Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1236.06
ACHN's Cash to Debt is ranked higher than
56% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. ACHN: 1236.06 )
Ranked among companies with meaningful Cash to Debt only.
ACHN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 153 Max: No Debt
Current: 1236.06
F-Score: 7
Z-Score: 55.17
M-Score: 77.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.88
ACHN's Operating margin (%) is ranked higher than
67% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. ACHN: -6.88 )
Ranked among companies with meaningful Operating margin (%) only.
ACHN' s Operating margin (%) Range Over the Past 10 Years
Min: -17954.25  Med: -747.67 Max: 11879.49
Current: -6.88
-17954.25
11879.49
Net-margin (%) 10.08
ACHN's Net-margin (%) is ranked higher than
80% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. ACHN: 10.08 )
Ranked among companies with meaningful Net-margin (%) only.
ACHN' s Net-margin (%) Range Over the Past 10 Years
Min: -17897.17  Med: -713.8 Max: 12030.34
Current: 10.08
-17897.17
12030.34
ROE (%) 1.69
ACHN's ROE (%) is ranked higher than
77% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ACHN: 1.69 )
Ranked among companies with meaningful ROE (%) only.
ACHN' s ROE (%) Range Over the Past 10 Years
Min: -199.15  Med: -77.16 Max: 1.69
Current: 1.69
-199.15
1.69
ROA (%) 1.59
ACHN's ROA (%) is ranked higher than
79% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. ACHN: 1.59 )
Ranked among companies with meaningful ROA (%) only.
ACHN' s ROA (%) Range Over the Past 10 Years
Min: -103.25  Med: -61.16 Max: 1.59
Current: 1.59
-103.25
1.59
ROC (Joel Greenblatt) (%) 308.58
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. ACHN: 308.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACHN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6066.62  Med: -2847.52 Max: 308.58
Current: 308.58
-6066.62
308.58
Revenue Growth (3Y)(%) -100.00
ACHN's Revenue Growth (3Y)(%) is ranked lower than
96% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ACHN: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACHN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: -40.7
Current: -100
EBITDA Growth (3Y)(%) 0.50
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. ACHN: 0.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACHN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -41 Max: 4.3
Current: 0.5
0
4.3
EPS Growth (3Y)(%) 0.50
ACHN's EPS Growth (3Y)(%) is ranked higher than
55% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ACHN: 0.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACHN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.5  Med: -26.6 Max: 3.4
Current: 0.5
-65.5
3.4
» ACHN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ACHN Guru Trades in Q3 2015

Steven Cohen 9,772,018 sh (+16.50%)
Paul Tudor Jones Sold Out
» More
Q4 2015

ACHN Guru Trades in Q4 2015

Jim Simons 111,400 sh (New)
Steven Cohen 8,966,608 sh (-8.24%)
» More
Q1 2016

ACHN Guru Trades in Q1 2016

Joel Greenblatt 554,125 sh (New)
Paul Tudor Jones 39,959 sh (New)
Steven Cohen 9,103,921 sh (+1.53%)
Jim Simons Sold Out
» More
Q2 2016

ACHN Guru Trades in Q2 2016

Steven Cohen 8,987,615 sh (-1.28%)
Paul Tudor Jones 19,846 sh (-50.33%)
Joel Greenblatt 191,792 sh (-65.39%)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SRPT, NAS:CEMP, NAS:SAGE, NAS:FGEN, NAS:ACOR, NAS:INSY, NAS:AAAP, NYSE:EBS, NAS:DERM, NAS:FPRX, NAS:HALO, NAS:XLRN, OTCPK:PFSCF, OTCPK:MPSYY, NAS:PTLA, OTCPK:BVNKF, NAS:CHRS, NAS:TBPH, NAS:MGNX, NAS:RGEN » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases like hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free.

Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.

Ratios

vs
industry
vs
history
P/E(ttm) 142.29
ACHN's P/E(ttm) is ranked lower than
88% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 28.72 vs. ACHN: 142.29 )
Ranked among companies with meaningful P/E(ttm) only.
ACHN' s P/E(ttm) Range Over the Past 10 Years
Min: 0.36  Med: 0.63 Max: 160.67
Current: 142.29
0.36
160.67
PE(NRI) 142.29
ACHN's PE(NRI) is ranked lower than
87% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACHN: 142.29 )
Ranked among companies with meaningful PE(NRI) only.
ACHN' s PE(NRI) Range Over the Past 10 Years
Min: 0.36  Med: 0.63 Max: 160.67
Current: 142.29
0.36
160.67
P/B 2.82
ACHN's P/B is ranked higher than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ACHN: 2.82 )
Ranked among companies with meaningful P/B only.
ACHN' s P/B Range Over the Past 10 Years
Min: 0.79  Med: 3.69 Max: 12.16
Current: 2.82
0.79
12.16
P/S 17.29
ACHN's P/S is ranked lower than
61% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. ACHN: 17.29 )
Ranked among companies with meaningful P/S only.
ACHN' s P/S Range Over the Past 10 Years
Min: 0.84  Med: 249.19 Max: 7995
Current: 17.29
0.84
7995
PFCF 474.43
ACHN's PFCF is ranked lower than
98% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. ACHN: 474.43 )
Ranked among companies with meaningful PFCF only.
ACHN' s PFCF Range Over the Past 10 Years
Min: 446.11  Med: 3630 Max: 4550
Current: 474.43
446.11
4550
POCF 284.71
ACHN's POCF is ranked lower than
98% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. ACHN: 284.71 )
Ranked among companies with meaningful POCF only.
ACHN' s POCF Range Over the Past 10 Years
Min: 267.67  Med: 726 Max: 910
Current: 284.71
267.67
910
EV-to-EBIT 110.58
ACHN's EV-to-EBIT is ranked lower than
90% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. ACHN: 110.58 )
Ranked among companies with meaningful EV-to-EBIT only.
ACHN' s EV-to-EBIT Range Over the Past 10 Years
Min: -213.5  Med: -3.7 Max: 132.9
Current: 110.58
-213.5
132.9
EV-to-EBITDA 98.68
ACHN's EV-to-EBITDA is ranked lower than
90% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. ACHN: 98.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACHN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -264.5  Med: -3.7 Max: 118.7
Current: 98.68
-264.5
118.7
Shiller P/E 12.13
ACHN's Shiller P/E is ranked higher than
84% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.61 vs. ACHN: 12.13 )
Ranked among companies with meaningful Shiller P/E only.
ACHN' s Shiller P/E Range Over the Past 10 Years
Min: 11.47  Med: 12.5 Max: 13.77
Current: 12.13
11.47
13.77
Current Ratio 33.43
ACHN's Current Ratio is ranked higher than
98% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. ACHN: 33.43 )
Ranked among companies with meaningful Current Ratio only.
ACHN' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.56 Max: 33.43
Current: 33.43
1.06
33.43
Quick Ratio 33.43
ACHN's Quick Ratio is ranked higher than
98% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ACHN: 33.43 )
Ranked among companies with meaningful Quick Ratio only.
ACHN' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.56 Max: 33.43
Current: 33.43
1.06
33.43
Days Sales Outstanding 4.89
ACHN's Days Sales Outstanding is ranked higher than
92% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. ACHN: 4.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACHN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.89  Med: 37.82 Max: 152.21
Current: 4.89
4.89
152.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.10
ACHN's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ACHN: -14.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACHN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -274.8  Med: -41.1 Max: -14.1
Current: -14.1
-274.8
-14.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.83
ACHN's Price/Net Cash is ranked higher than
76% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ACHN: 2.83 )
Ranked among companies with meaningful Price/Net Cash only.
ACHN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.82  Med: 5.16 Max: 12.7
Current: 2.83
0.82
12.7
Price/Net Current Asset Value 2.81
ACHN's Price/Net Current Asset Value is ranked higher than
76% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ACHN: 2.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACHN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.78  Med: 4.84 Max: 12.29
Current: 2.81
0.78
12.29
Price/Tangible Book 2.78
ACHN's Price/Tangible Book is ranked higher than
67% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ACHN: 2.78 )
Ranked among companies with meaningful Price/Tangible Book only.
ACHN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.72  Med: 4.32 Max: 81.84
Current: 2.78
0.72
81.84
Price/Median PS Value 0.07
ACHN's Price/Median PS Value is ranked higher than
98% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ACHN: 0.07 )
Ranked among companies with meaningful Price/Median PS Value only.
ACHN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.6 Max: 17.5
Current: 0.07
0.01
17.5
Price/Graham Number 4.19
ACHN's Price/Graham Number is ranked lower than
64% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. ACHN: 4.19 )
Ranked among companies with meaningful Price/Graham Number only.
ACHN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.21  Med: 0.36 Max: 4.55
Current: 4.19
0.21
4.55
Earnings Yield (Greenblatt) (%) 0.98
ACHN's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ACHN: 0.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACHN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 299 Max: 15068.8
Current: 0.98
0.8
15068.8

More Statistics

Revenue (TTM) (Mil) $66.12
EPS (TTM) $ 0.06
Beta2.26
Short Percentage of Float11.61%
52-Week Range $5.57 - 10.95
Shares Outstanding (Mil)136.68

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 150 260
EPS ($) -0.55 0.09 1.60
EPS w/o NRI ($) -0.55 0.09 1.60
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Gilead Sciences: Still Dominating Hepatitis C But… Aug 17 2016
ACHILLION PHARMACEUTICALS INC Financials Aug 12 2016
Is Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now? Aug 12 2016
Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored... Aug 11 2016
ETF’s with exposure to Achillion Pharmaceuticals, Inc. : August 9, 2016 Aug 09 2016
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference Aug 09 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Aug 08 2016
Achillion Reports Second Quarter 2016 Financial Results Aug 04 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 04 2016
Achillion Reports Second Quarter 2016 Financial Results Aug 04 2016
Q2 2016 Achillion Pharmaceuticals Inc Earnings Release - Tentative - Before Market Open Aug 04 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US :... Jul 20 2016
Coverage initiated on Achillion Pharma by Chardan Capital Markets Jul 14 2016
5 Analyst Stock Picks Under $10 With Massive Upside Calls Jul 10 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Jul 08 2016
Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades Jul 07 2016
Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More Jul 07 2016
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : June 21, 2016 Jun 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)